---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-22-000096"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:31:07.403105+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q2 2022 revenue $419.4M, cabozantinib net product revenue $347M, GAAP EPS $0.22

## Summary
- Total revenues $419.4M, up from $385.2M in Q2 2021; cabozantinib franchise net product revenue $347.0M, up 22% YoY.
- GAAP net income $70.7M ($0.22 diluted EPS) vs $96.1M ($0.30) in Q2 2021; non-GAAP EPS $0.28.
- Cash and investments $2.0B at June 30, 2022, up from $1.9B at year-end 2021.
- Positive PFS data for COSMIC-313; initiated STELLAR-303 phase 3 for XL092 and phase 1 for XL114.
- Signed business development agreements with BioInvent and Ryvu Therapeutics to expand biologics capabilities.

## SEC filing metadata
- accession: 0000939767-22-000096
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976722000096/0000939767-22-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976722000096/exel-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-22-000096
- JSON: https://secwatch.observer/filing/0000939767-22-000096.json
- Plain text: https://secwatch.observer/filing/0000939767-22-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.